DK0987256T3 - Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid - Google Patents

Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid

Info

Publication number: DK0987256T3
Authority: DK; Denmark
Prior art keywords: methylisoxazole; trifluoromethylphenyl; carboxylic acid; acid amide; crystal form
Prior art date: 1997-08-08

Application number

DK99117098T

Other languages

English (en)

Inventor

Holger Dr Faasch

Udo Dr Hedtmann

Erich Dr Paulus

Uwe Dr Westenfelder

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-08

Filing date

1998-07-31

Publication date

2002-02-11

1997-08-08 Priority claimed from DE19734438A external-priority patent/DE19734438A1/de

1997-12-17 Priority claimed from DE1997156093 external-priority patent/DE19756093A1/de

1998-07-31 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2002-02-11 Application granted granted Critical

2002-02-11 Publication of DK0987256T3 publication Critical patent/DK0987256T3/da

Links

239000013078 crystal Substances 0.000 title 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK99117098T 1997-08-08 1998-07-31 Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid DK0987256T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19734438A DE19734438A1 (de)	1997-08-08	1997-08-08	Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid
DE1997156093 DE19756093A1 (de)	1997-12-17	1997-12-17	Verfahren zur Herstellung einer Kristallform von N-(4-Trifluormethylphenyl)-5-methyl-isoxazole-4-carboxamid

Publications (1)

Publication Number	Publication Date
DK0987256T3 true DK0987256T3 (da)	2002-02-11

Family

ID=26038983

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK99117098T DK0987256T3 (da)	1997-08-08	1998-07-31	Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
DK98114373T DK0903345T3 (da)	1997-08-08	1998-07-31	Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK98114373T DK0903345T3 (da)	1997-08-08	1998-07-31	Krystalform af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Country Status (28)

Country	Link
US (5)	US6060494A (da)
EP (2)	EP0903345B1 (da)
JP (2)	JPH11124372A (da)
KR (2)	KR100544041B1 (da)
CN (2)	CN1089759C (da)
AR (1)	AR015418A1 (da)
AT (2)	ATE196764T1 (da)
AU (1)	AU752764B2 (da)
BR (1)	BR9806568A (da)
CA (1)	CA2245267C (da)
CZ (3)	CZ301426B6 (da)
DE (2)	DE59801792D1 (da)
DK (2)	DK0987256T3 (da)
ES (2)	ES2150808T3 (da)
GR (1)	GR3034814T3 (da)
HK (1)	HK1049481B (da)
HU (2)	HU229232B1 (da)
ID (1)	ID20667A (da)
IL (1)	IL125671A (da)
NO (1)	NO310871B1 (da)
NZ (1)	NZ331270A (da)
PL (1)	PL192126B1 (da)
PT (2)	PT987256E (da)
RU (1)	RU2224753C2 (da)
SK (2)	SK285216B6 (da)
TR (2)	TR199801513A2 (da)
TW (1)	TW593288B (da)
UA (1)	UA54411C2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE196764T1 (de) *	1997-08-08	2000-10-15	Aventis Pharma Gmbh	Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid
DE19908527C2 (de)	1999-02-26	2001-08-30	Aventis Pharma Gmbh	Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) *	1999-12-16	2003-04-16	特瓦制药工业有限公司	制备来氟米特的新方法和新晶形的来氟米特
CA2400290A1 (en) *	2000-02-15	2001-08-23	Teva Pharmaceutical Industries Ltd.	A method for synthesizing leflunomide
CA2429426A1 (en) *	2000-11-17	2002-05-23	Takeda Chemical Industries, Ltd.	Isoxazole derivatives
GB0123571D0 (en)	2001-04-05	2001-11-21	Aventis Pharm Prod Inc	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7429593B2 (en)	2001-09-14	2008-09-30	Shionogi & Co., Ltd.	Utilities of amide compounds
AU2003207055A1 (en) *	2002-02-12	2003-09-04	Sumitomo Pharmaceuticals Co., Ltd.	Novel drugs for external use
US20050158371A1 (en) *	2002-02-12	2005-07-21	Sumitomo Pharmaceuticals Co., Ltd.	Novel external agent
US20060135547A1 (en) *	2003-03-12	2006-06-22	Toth Zoltan G	Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
WO2004080461A2 (en) *	2003-03-12	2004-09-23	TEVA Gyógyszergyár Részvénytársaság	Stable pharmaceutical compositions of desloratadine
JP4223428B2 (ja) *	2004-03-31	2009-02-12	富士通メディアデバイス株式会社	フィルタおよびその製造方法
WO2007067710A1 (en) *	2005-12-08	2007-06-14	Amphora Discovery Corporation	Certain chemical entities, compositions, and methods for modulating trpv1
CN101143834B (zh) *	2006-09-15	2010-09-08	欣凯医药化工中间体（上海）有限公司	N-(4-三氟甲基苯)-2-氰基-3-羟基丁烯酰胺钠盐的多晶型及其制备方法
JP2011513202A (ja) *	2008-03-10	2011-04-28	武田薬品工業株式会社	ベンズイミダゾール化合物の結晶
US20120172427A1 (en)	2009-09-18	2012-07-05	Sanofi	(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability
CN103977594B (zh) *	2014-06-03	2016-02-17	江苏九九久科技股份有限公司	一种结晶方法
US9895370B2 (en) *	2015-11-19	2018-02-20	Pharmedix.Co., Ltd	Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
CN109180599A (zh) *	2018-09-03	2019-01-11	深圳市新阳唯康科技有限公司	一种来氟米特新晶型化合物及其制备方法
CN112898215B (zh) *	2021-02-04	2022-11-08	美罗药业股份有限公司	一种来氟米特晶型i的制备方法
CN114716388B (zh) *	2021-11-04	2024-02-13	江苏冠军科技集团股份有限公司	一种磺胺-银化合物及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL186239B (nl) *	1975-06-05		Hoechst Ag	Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
NL178596C (nl) *	1975-06-05	1986-04-16	Hoechst Ag	Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2524959C2 (de) *	1975-06-05	1983-02-10	Hoechst Ag, 6000 Frankfurt	5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel
DE2525959A1 (de) *	1975-06-11	1977-02-10	Focke Pfuhl Verpack Automat	Verpackung fuer zigaretten, zigarillos etc.
DE2854439A1 (de) *	1978-12-16	1980-07-03	Hoechst Ag	Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
IL63968A (en) *	1980-10-01	1985-10-31	Glaxo Group Ltd	Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4935434A (en) *	1988-01-26	1990-06-19	Bristol-Myers Company	Antiarthritic isoxazole-4-carboxamides
US5583150A (en) *	1989-08-18	1996-12-10	Alcon Laboratories, Inc.	5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
DE59010701D1 (de) *	1990-05-18	1997-05-22	Hoechst Ag	Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
GB9115377D0 (en) *	1991-07-17	1991-09-04	Rhone Poulenc Agriculture	New compositions of matter
DE4127737A1 (de) *	1991-08-22	1993-02-25	Hoechst Ag	Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
GB9209330D0 (en) *	1992-04-30	1992-06-17	Roussel Lab Ltd	Chemical compounds
ES2124800T3 (es) *	1993-01-08	1999-02-16	Hoechst Ag	Empleo de leflunomida para la inhibicion de interleuquina 1 beta.
DE59407414D1 (de) *	1993-01-08	1999-01-21	Hoechst Ag	Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
EP0607777B1 (de) *	1993-01-08	1998-12-09	Hoechst Aktiengesellschaft	Verwendung von Leflunomid zur Hemmung von Interleukin 8
TW314467B (da) *	1993-03-31	1997-09-01	Hoechst Ag
GB9320299D0 (en) *	1993-10-01	1993-11-17	Roussel Lab Ltd	Isoxazole derivatives
US5610173A (en) *	1994-01-07	1997-03-11	Sugen, Inc.	Formulations for lipophilic compounds
KR100365064B1 (ko) *	1994-10-17	2003-04-11	훽스트파마슈티칼스앤드케미칼스가부시키가이샤	I형알레르기성질환의예방및치료제
SK283608B6 (sk) *	1995-02-06	2003-10-07	Smithkline Beecham Plc	Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
DE19539638A1 (de) *	1995-10-25	1997-04-30	Hoechst Ag	Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
US6316479B1 (en) *	1997-05-19	2001-11-13	Sugen, Inc.	Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
HRP980291A2 (en) *	1997-06-16	1999-04-30	Lin-Hua Zhang	Crystalline roxifiban
ATE196764T1 (de) *	1997-08-08	2000-10-15	Aventis Pharma Gmbh	Kristallform von 5-methylisoxazol-4-carbonsäure- (4-trifluormethyl)-anilid
US6096770A (en) *	1998-08-03	2000-08-01	American Home Products Corporation	Anthranilic acid analogs
DE19908527C2 (de) *	1999-02-26	2001-08-30	Aventis Pharma Gmbh	Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
CN1411373A (zh) *	1999-12-16	2003-04-16	特瓦制药工业有限公司	制备来氟米特的新方法和新晶形的来氟米特
CA2400290A1 (en) *	2000-02-15	2001-08-23	Teva Pharmaceutical Industries Ltd.	A method for synthesizing leflunomide
US6727272B1 (en) *	2002-07-15	2004-04-27	Unitech Pharmaceuticals, Inc.	Leflunomide analogs for treating rheumatoid arthritis

1998
- 1998-07-31 AT AT98114373T patent/ATE196764T1/de active
- 1998-07-31 AT AT99117098T patent/ATE207065T1/de active
- 1998-07-31 DK DK99117098T patent/DK0987256T3/da active
- 1998-07-31 ES ES98114373T patent/ES2150808T3/es not_active Expired - Lifetime
- 1998-07-31 DE DE59801792T patent/DE59801792D1/de not_active Expired - Lifetime
- 1998-07-31 DK DK98114373T patent/DK0903345T3/da active
- 1998-07-31 PT PT99117098T patent/PT987256E/pt unknown
- 1998-07-31 DE DE59800287T patent/DE59800287D1/de not_active Expired - Lifetime
- 1998-07-31 EP EP98114373A patent/EP0903345B1/de not_active Expired - Lifetime
- 1998-07-31 ES ES99117098T patent/ES2166205T3/es not_active Expired - Lifetime
- 1998-07-31 PT PT98114373T patent/PT903345E/pt unknown
- 1998-07-31 EP EP99117098A patent/EP0987256B1/de not_active Expired - Lifetime
- 1998-08-05 IL IL12567198A patent/IL125671A/en not_active IP Right Cessation
- 1998-08-05 CZ CZ20032983A patent/CZ301426B6/cs not_active IP Right Cessation
- 1998-08-05 CZ CZ20032982A patent/CZ301514B6/cs not_active IP Right Cessation
- 1998-08-05 CZ CZ19982468A patent/CZ292943B6/cs not_active IP Right Cessation
- 1998-08-06 US US09/129,783 patent/US6060494A/en not_active Expired - Lifetime
- 1998-08-06 TR TR1998/01513A patent/TR199801513A2/xx unknown
- 1998-08-06 TR TR2006/00582A patent/TR200600582A1/xx unknown
- 1998-08-06 UA UA98084307A patent/UA54411C2/uk unknown
- 1998-08-06 NZ NZ331270A patent/NZ331270A/xx not_active IP Right Cessation
- 1998-08-06 AR ARP980103900A patent/AR015418A1/es active IP Right Grant
- 1998-08-06 TW TW087112927A patent/TW593288B/zh not_active IP Right Cessation
- 1998-08-06 SK SK1521-2001A patent/SK285216B6/sk not_active IP Right Cessation
- 1998-08-06 ID IDP981098A patent/ID20667A/id unknown
- 1998-08-06 SK SK1058-98A patent/SK282641B6/sk not_active IP Right Cessation
- 1998-08-07 HU HU0700190A patent/HU229232B1/hu unknown
- 1998-08-07 KR KR1019980032110A patent/KR100544041B1/ko not_active Expired - Lifetime
- 1998-08-07 HU HU9801844A patent/HU225870B1/hu unknown
- 1998-08-07 CN CN98116235A patent/CN1089759C/zh not_active Expired - Lifetime
- 1998-08-07 RU RU98115390/04A patent/RU2224753C2/ru active
- 1998-08-07 PL PL327901A patent/PL192126B1/pl unknown
- 1998-08-07 NO NO19983632A patent/NO310871B1/no not_active IP Right Cessation
- 1998-08-07 JP JP10224015A patent/JPH11124372A/ja active Pending
- 1998-08-07 CA CA002245267A patent/CA2245267C/en not_active Expired - Lifetime
- 1998-08-07 BR BR9806568-8A patent/BR9806568A/pt not_active Application Discontinuation
- 1998-08-07 AU AU78870/98A patent/AU752764B2/en not_active Expired
- 1998-08-07 CN CNB021045747A patent/CN1181064C/zh not_active Expired - Lifetime
1999
- 1999-10-28 US US09/428,499 patent/US6221891B1/en not_active Expired - Lifetime
2000
- 2000-11-10 GR GR20000402501T patent/GR3034814T3/el unknown
2001
- 2001-01-19 US US09/764,258 patent/US6552202B2/en not_active Expired - Lifetime
2002
- 2002-11-25 US US10/302,872 patent/US6900334B2/en not_active Expired - Lifetime
2003
- 2003-02-19 HK HK03101247.6A patent/HK1049481B/zh not_active IP Right Cessation
2004
- 2004-04-23 US US10/830,307 patent/US6995272B2/en not_active Expired - Lifetime
2005
- 2005-06-28 KR KR1020050056044A patent/KR100588254B1/ko not_active Expired - Lifetime
2009
- 2009-07-28 JP JP2009175137A patent/JP2009280604A/ja active Pending

Also Published As

Publication number	Publication date
HK1017681A1 (en)	1999-11-26
TW593288B (en)	2004-06-21
CA2245267C (en)	2008-12-23
CZ301514B6 (cs)	2010-03-31
US20030166945A1 (en)	2003-09-04
NO983632D0 (no)	1998-08-07
IL125671A0 (en)	1999-04-11
KR100544041B1 (ko)	2006-09-18
ES2166205T3 (es)	2002-04-01
HUP9801844A2 (hu)	2000-02-28
JPH11124372A (ja)	1999-05-11
EP0987256B1 (de)	2001-10-17
PL192126B1 (pl)	2006-09-29
TR199801513A3 (tr)	1999-02-22
DE59801792D1 (de)	2001-11-22
HU0700190D0 (en)	2007-05-02
KR20050077498A (ko)	2005-08-02
AR015418A1 (es)	2001-05-02
CN1089759C (zh)	2002-08-28
NZ331270A (en)	2000-04-28
US20040204465A1 (en)	2004-10-14
HU225870B1 (en)	2007-11-28
TR200600582A1 (tr)	2006-08-21
AU7887098A (en)	1999-02-18
EP0903345A1 (de)	1999-03-24
EP0987256A1 (de)	2000-03-22
KR19990023433A (ko)	1999-03-25
NO983632L (no)	1999-02-09
ATE196764T1 (de)	2000-10-15
DE59800287D1 (de)	2000-11-09
DK0903345T3 (da)	2000-10-23
HK1049481A1 (en)	2003-05-16
ATE207065T1 (de)	2001-11-15
SK282641B6 (sk)	2002-10-08
HU9801844D0 (en)	1998-10-28
CZ246898A3 (cs)	1999-02-17
ID20667A (id)	1999-02-11
SK285216B6 (sk)	2006-09-07
CN1181064C (zh)	2004-12-22
BR9806568A (pt)	2000-05-16
PL327901A1 (en)	1999-02-15
ES2150808T3 (es)	2000-12-01
PT987256E (pt)	2002-03-28
PT903345E (pt)	2001-01-31
US6995272B2 (en)	2006-02-07
HUP9801844A3 (en)	2000-04-28
HK1049481B (zh)	2005-07-08
EP0903345B1 (de)	2000-10-04
CZ292943B6 (cs)	2004-01-14
US6060494A (en)	2000-05-09
CA2245267A1 (en)	1999-02-08
NO310871B1 (no)	2001-09-10
US6552202B2 (en)	2003-04-22
GR3034814T3 (en)	2001-02-28
SK105898A3 (en)	1999-02-11
RU2224753C2 (ru)	2004-02-27
AU752764B2 (en)	2002-09-26
US6221891B1 (en)	2001-04-24
CN1373126A (zh)	2002-10-09
HU229232B1 (en)	2013-09-30
UA54411C2 (uk)	2003-03-17
TR199801513A2 (xx)	1999-02-22
US6900334B2 (en)	2005-05-31
CZ301426B6 (cs)	2010-02-24
US20030027851A1 (en)	2003-02-06
CN1208034A (zh)	1999-02-17
KR100588254B1 (ko)	2006-06-12
JP2009280604A (ja)	2009-12-03
IL125671A (en)	2002-11-10

Publication	Publication Date	Title
DK0987256T3 (da)	2002-02-11	Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
DK0923585T3 (da)	2002-07-01	Phosphinatbaserede inhibitorer af matrixmetalloproteinaser
DE69800430D1 (de)	2001-01-25	Modulatoren von durch Aminosäuren anregbare Rezeptoren
ID24247A (id)	2000-07-13	Penjajaran cetakan tunggal
IS4564A (is)	1997-09-22	Framleiðsla og kristalform af 2-methýl-thíeno-bensodíasepín
NO331016B1 (no)	2011-09-12	Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat
DE69812007D1 (de)	2003-04-17	Aliphatische Lösungen von Aminoalkyllithiumverbindungen
CY2012029I2 (el)	2015-08-05	Nεα μορφη της 5-ομεπραζολης
IS5098A (is)	1999-06-29	Ný afbrigði af 2-amínó-4(4-flúorbensýlamínó)-1-etoxýkarbónýl-amínóbensen og aðferðir við framleiðslu þeirra
DE69928195D1 (de)	2005-12-15	Komplettierung von Untrerdruck-Bohrlöchern
FI962932L (fi)	1996-09-20	Ankkuriproteiinifunktion modulaattoreita
DK38293D0 (da)	1993-03-31	Fremstilling af proteiner
ID28779A (id)	2001-07-05	BENTUK-BENTUK KRISTAL DARI EtO2C-CH2-(R)CgL-Aze-Pab-OH
NL300284I2 (nl)	2007-11-01	Kristalmodificatie van
DK1533303T3 (da)	2013-07-29	Substituerede aminosalicylsyreamider (mellemprodukter)
FI960425A7 (fi)	1996-08-02	Fenyylisykloheksyylikarboksyylihappoamidien käyttö
DK1102747T3 (da)	2003-09-29	Krystalformer af osenetant
DK0905128T3 (da)	2002-03-25	Fremgangsmåder og mellemprodukter egnede til fremstilling af antifolater
DK0980241T3 (da)	2004-04-05	Gelatineindkapslede opløsningsdosisformer af sertralin
DE69927626D1 (de)	2006-02-23	Ausführung von Permutationen
ID23885A (id)	2000-05-25	Bentuk-bentuk polimorf baru dari cypamfylline
DK1155004T3 (da)	2004-04-13	Fremgangsmåde til krystallisation af N-(4-trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
DK1098871T3 (da)	2003-10-27	Phenylesterderivater af alfa-aminosyrer
DK0840609T3 (da)	2002-09-30	Anvendelse af usubstituerede og substituerede N-(pyrrol-1-yl)pyridinaminer som antikonvulsive midler
IS5544A (is)	2000-06-21	Nýtt fosfatsalt af ísóprópýl-metýl-[2-(3-n-própoxýfenoxý)-etýl]amíni